In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Adaptimmune nets $178mm in IPO

Executive Summary

Less than a year after closing its $104mm Series A round (the largest Series A in 2014), UK-based Adaptimmune Therapeutics PLC (T-cell therapy) netted $178mm in its US initial public offering of 11.2mm ADSs (representing 67.5mm ordinary shares) for $17. The company planned to sell 9.4mm ADSs (representing 56.2mm ordinary shares) for $15-17.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies